|
Levodopa in the treatment of Parkinson's disease |
|
|
1 | (16) |
|
|
Changing dopamine agonist treatment in Parkinson's disease: experiences with switching to pramipexole |
|
|
17 | (10) |
|
|
|
|
|
|
The DONPAD-study -- Treatment of dementia in patients with Parkinson's disease with donepezil |
|
|
27 | (4) |
|
|
|
|
|
|
|
PD-related psychosis: pathophysiology with therapeutical strategies |
|
|
31 | (8) |
|
|
Antioxidant capacity in postmortem brain tissues of Parkinson's and Alzheimer's diseases |
|
|
39 | (6) |
|
|
|
|
|
|
|
|
|
Apoptosis inhibition in T cells triggers the expression of proinflammatory cytokines -- implications for the CNS |
|
|
45 | (8) |
|
|
|
|
|
Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: possible implications of glial cells |
|
|
53 | (14) |
|
|
|
Involvement of type A monoamine oxidase in neurodegeneration: regulation of mitochondrial signaling leading to cell death or neuroprotection |
|
|
67 | (12) |
|
|
|
|
|
|
The relationship of early studies of monoamine oxidase to present concepts |
|
|
79 | (8) |
|
|
Isatin, an endogenous MAO inhibitor, and a rat model of Parkinson's disease induced by the Japanese encephalitis virus |
|
|
87 | (10) |
|
|
|
|
|
|
|
|
|
Isatin interaction with glyceraldehyde-3-phosphate dehydrogenase, a putative target of neuroprotective drugs: partial agonism with deprenyl |
|
|
97 | (8) |
|
|
|
|
|
|
|
|
|
Inhibition of amine oxidases by the histamine-1 receptor antagonist hydroxyzine |
|
|
105 | (8) |
|
|
|
|
|
Neuroprotection for Parkinson's disease |
|
|
113 | (10) |
|
|
Marker for a preclinical diagnosis of Parkinson's disease as a basis for neuroprotection |
|
|
123 | (10) |
|
|
Assessing neuroprotection in Parkinson's disease: from the animal models to molecular neuroimaging in vivo |
|
|
133 | (10) |
|
|
|
|
|
Deprenyl: from chemical synthesis to neuroprotection |
|
|
143 | (14) |
|
|
|
|
|
The use of rasagiline in Parkinson's disease |
|
|
157 | (6) |
|
|
Novel neuroprotective neurotrophic NAP analogs targeting metal toxicity and oxidative stress: potential candidates for the control of neurodegenerative diseases |
|
|
163 | (10) |
|
|
|
|
Acute and chronic effects of developmental iron deficiency on mRNA expression patterns in the brain |
|
|
173 | (24) |
|
|
|
|
|
|
|
|
|
Long lasting effects of infancy iron deficiency -- Preliminary results |
|
|
197 | (4) |
|
|
|
Altered regulation of iron transport and storage in Parkinson's disease |
|
|
201 | (4) |
|
|
Iron dyshomeostasis in Parkinson's disease |
|
|
205 | (10) |
|
|
|
|
Cerebral oligemia and iron influence in cerebral structures -- element of Morbus Parkinson Models? |
|
|
215 | (14) |
|
|
|
|
|
|
|
Impact of selenium, iron, copper and zinc in on/off Parkinson's patients on L-dopa therapy |
|
|
229 | (8) |
|
|
|
|
|
Metal specificity of an iron-responsive element in Alzheimer's APP mRNA 5'untranslated region, tolerance of SH-SY5Y and H4 neural cells to desferrioxamine, clioquinol, VK-28, and a piperazine chelator |
|
|
237 | (12) |
|
|
|
|
|
|
|
Green tea catechins as brain-permeable, non toxic iron chelators to ``iron out iron'' from the brain |
|
|
249 | (10) |
|
|
|
|
|
Index |
|
259 | |